NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX - News), an international pharmaceutical manufacturer and marketer, today announced that fully diluted reported earnings per share equaled $0.71 in the second quarter of fiscal 2008, a decrease of 5% over last year's second quarter's fully diluted reported earnings per share of $0.75. Reported earnings per share were reduced by the effect of a $70 million licensing charge, equivalent to $0.15 per share net of tax, to Microbia, Inc. for the right to co-develop and co-market linaclotide, a compound being investigated for chronic constipation and constipation predominant irritable bowel syndrome.
